Recludix Pharma
Dr. Gallagher is a Venture Partner at NEA. Dr. Gallagher is a proven entrepreneur, operator, and more recently investor with over 30 years of experience in commercial, drug development, and business development roles. Prio r to joining NEA, she was a Venture Partner with Frazier Healthcare. Since 2011, she has served as an independent director on multiple boards of biopharma companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. Prior to Calistoga Pharmaceuticals, she had a long career with various operating roles at both large and small biopharma companies. She also serves as a director at AtaraBio, Certara, Chromacode, PIONYR Immunotherapeutics, Qpex BioPharma, T Rex Bio, and Turning Point Therapeutics.
This person is not in the org chart
This person is not in any offices
Recludix Pharma
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.